REFERENCES
1. Antzelevitch C, Burashnikov A. Overview of basic mechanisms of cardiac arrhythmia. Card Electrophysiol Clin. 2011;3:23-45.
2. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11:639-54.
3. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16:217-21.
4. Yuyun MF, Bonny A, Ng GA, et al. A systematic review of the spectrum of cardiac arrhythmias in sub-saharan africa. Glob Heart. 2020;15:37.
5. Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990-2017: results from the global burden of disease study 2017. Eur Heart J Qual Care Clin Outcomes. 2021;7:574-82.
6. Chen Q, Yi Z, Cheng J. Atrial fibrillation in aging population. Aging Med (Milton). 2018;1:67-74.
7. Tellez JO, Mczewski M, Yanni J, et al. Ageing-dependent remodelling of ion channel and Ca2+ clock genes underlying sino-atrial node pacemaking. Exp Physiol. 2011;96:1163-78.
8. Murakoshi N, Aonuma K. Epidemiology of arrhythmias and sudden cardiac death in Asia. Circ J. 2013;77:2419-31.
9. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746-51.
10. Murphy A, Banerjee A, Breithardt G, et al. The world heart federation roadmap for nonvalvular atrial fibrillation. Glob Heart. 2017;12:273-84.
11. Wolfes J, Ellermann C, Frommeyer G, Eckardt L. Evidence-based treatment of atrial fibrillation around the globe: comparison of the latest ESC, AHA/ACC/HRS, and CCS guidelines on the management of atrial fibrillation. Rev Cardiovasc Med. 2022;23:56.
12. Singh BN, Nademanee K. Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. Am Heart J. 1983;106:857-69.
13. Herendael H, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag. 2010;6:465-72.
14. Wang Z, Tong Q, Li T, Qian Y. Nano drugs delivery system: a novel promise for the treatment of atrial fibrillation. Front Cardiovasc Med. 2022;9:906350.
15. Poole JE, Bahnson TD, Monahan KH, et al; CABANA Investigators and ECG Rhythm Core Lab. Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial. J Am Coll Cardiol. 2020;75:3105-18.
16. Nadimi AE, Ebrahimipour SY, Afshar EG, et al. Nano-scale drug delivery systems for antiarrhythmic agents. Eur J Med Chem. 2018;157:1153-63.
17. Smith BR, Edelman ER. Nanomedicines for cardiovascular disease. Nat Cardiovasc Res. 2023;2:351-67.
18. Li T, Liang W, Xiao X, Qian Y. Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases. Int J Nanomedicine. 2018;13:7349-62.
19. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50:e1-e88.
20. Barra S, Primo J, Gonçalves H, Boveda S, Providência R, Grace A. Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?. Rev Port Cardiol. 2022;41:783-9.
21. Hayward C, Patel HC, Patel K, et al. The evolving landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. Eur Heart J Cardiovasc Pharmacother. 2016;2:90-4.
22. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9:CD005049.
23. Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498.
24. Goldschlager N, Epstein AE, Naccarelli GV, et al; Practice Guidelines Sub-committee. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4:1250-9.
25. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J. 1985;109:975-83.
26. Ward GH, Yalkowsky SH. Studies in phlebitis. VI: dilution-induced precipitation of amiodarone HCL. J Parenter Sci Technol. 1993;47:161-5.
27. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm. 2009;379:201-9.
28. Minkov I, Ivanova T, Panaiotov I, Proust J, Saulnier P. Reorganization of lipid nanocapsules at air-water interface: part 2. properties of the formed surface film. Colloids Surf B Biointerfaces. 2005;44:197-203.
29. Vonarbourg A, Saulnier P, Passirani C, Benoit JP. Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interface. Electrophoresis. 2005;26:2066-75.
30. Lamprecht A, Bouligand Y, Benoit JP. New lipid nanocapsules exhibit sustained release properties for amiodarone. J Control Release. 2002;84:59-68.
31. Lamprecht A, Ubrich N, Yamamoto H, et al. Design of rolipram-loaded nanoparticles: comparison of two preparation methods. J Control Release. 2001;71:297-306.
32. Polakovic M, Görner T, Gref R, Dellacherie E. Lidocaine loaded biodegradable nanospheres. II. modelling of drug release. J Control Release. 1999;60:169-77.
33. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8:102.
34. Takahama H, Shigematsu H, Asai T, et al. Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model. Cardiovasc Drugs Ther. 2013;27:125-32.
35. Zhuge Y, Zheng ZF, Xie MQ, Li L, Wang F, Gao F. Preparation of liposomal amiodarone and investigation of its cardiomyocyte-targeting ability in cardiac radiofrequency ablation rat model. Int J Nanomedicine. 2016;11:2359-67.
36. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems - an overview. Adv Colloid Interface Sci. 2012;183-184:46-54.
37. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22-36.
38. Teaima MH, Helal DA, Alsofany JM, El-Nabarawi MA, Yasser M. Ion-triggered in situ gelling intranasal spray of dronedarone hydrochloride nanocarriers: in vitro optimization and in vivo pharmacokinetic appraisal. Pharmaceutics. 2022;14:2405.
39. Ammar HO, Haider M, Ibrahim M, El Hoffy NM.
40. Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19:2965-74.
41. Arzani G, Haeri A, Daeihamed M, Bakhtiari-Kaboutaraki H, Dadashzadeh S. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomedicine. 2015;10:4797-813.
42. Alzhrani GN, Alanazi ST, Alsharif SY, et al. Exosomes: isolation, characterization, and biomedical applications. Cell Biol Int. 2021;45:1807-31.
43. Liu L, Zhang H, Mao H, Li X, Hu Y. Exosomal miR-320d derived from adipose tissue-derived MSCs inhibits apoptosis in cardiomyocytes with atrial fibrillation (AF). Artif Cells Nanomed Biotechnol. 2019;47:3976-84.
44. Zhang W, Man Y, Chen Z. microRNA-148a in exosomes derived from bone marrow mesenchymal stem cells alleviates cardiomyocyte apoptosis in atrial fibrillation by Inhibiting SMOC2. Mol Biotechnol. 2022;64:1076-87.
45. Huang S, Deng Y, Xu J, Liu J, Liu L, Fan C. The role of exosomes and their cargos in the mechanism, diagnosis, and treatment of atrial fibrillation. Front Cardiovasc Med. 2021;8:712828.
46. Salah E, Abouelfetouh MM, Pan Y, Chen D, Xie S. Solid lipid nanoparticles for enhanced oral absorption: a review. Colloids Surf B Biointerfaces. 2020;196:111305.
47. Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines. Vaccines (Basel). 2021;9:359.
48. Shah MK, Madan P, Lin S. Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model. Pharm Dev Technol. 2015;20:877-85.
49. Aboud HM, El Komy MH, Ali AA, El Menshawe SF, Abd Elbary A. Development, optimization, and evaluation of carvedilol-loaded solid lipid nanoparticles for intranasal drug delivery. AAPS PharmSciTech. 2016;17:1353-65.
50. Shelley H, Babu RJ. Role of Cyclodextrins in nanoparticle-based drug delivery systems. J Pharm Sci. 2018;107:1741-53.
51. Arima H, Hayashi Y, Higashi T, Motoyama K. Recent advances in cyclodextrin delivery techniques. Expert Opin Drug Deliv. 2015;12:1425-41.
52. Pandey A. Cyclodextrin-based nanoparticles for pharmaceutical applications: a review. Environ Chem Lett. 2021;19:4297-310.
53. Hulsmans M, Clauss S, Xiao L, et al. Macrophages facilitate electrical conduction in the heart. Cell. 2017;169:510-522.e20.
54. Weissleder R, Nahrendorf M, Pittet MJ. Imaging macrophages with nanoparticles. Nat Mater. 2014;13:125-38.
55. Ahmed MS, Rodell CB, Hulsmans M, et al. A supramolecular nanocarrier for delivery of amiodarone anti-arrhythmic therapy to the heart. Bioconjug Chem. 2019;30:733-40.
56. Schaffazick SR, Pohlmann AR, Dalla-Costa T, Guterres SS. Freeze-drying polymeric colloidal suspensions: nanocapsules, nanospheres and nanodispersion. A comparative study. Eur J Pharm Biopharm. 2003;56:501-5.
57. Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36:887-913.
58. Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26:64-70.
59. Kakkar A, Traverso G, Farokhzad OC, Weissleder R, Langer R. Evolution of macromolecular complexity in drug delivery systems. Nat Rev Chem. 2017;1:63.
60. Wong PT, Choi SK. Mechanisms of drug release in nanotherapeutic delivery systems. Chem Rev. 2015;115:3388-432.
61. Motawea A, Ahmed DAM, Eladl AS, El-Mansy AAE, Saleh NM. Appraisal of amiodarone-loaded PLGA nanoparticles for prospective safety and toxicity in a rat model. Life Sci. 2021;274:119344.
62. Castro KCD, Costa JM, Campos MGN. Drug-loaded polymeric nanoparticles: a review. Int J Polym Mater Polym Biomater. 2022;71:1-13.
63. Bernkop-Schnürch A, Dünnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm. 2012;81:463-9.
64. Buyuk NI, Arayici PP, Derman S, Mustafaeva Z, Yucel S. Synthesis of chitosan nanoparticles for controlled release of amiodarone. Indian J Pharm Sci. 2020;82:131-8.
65. Asad ZUA, Yousif A, Khan MS, Al-Khatib SM, Stavrakis S. Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circ Arrhythm Electrophysiol. 2019;12:e007414.
66. O'Quinn MP, Dormer KJ, Huizar JF, et al. Epicardial injection of nanoformulated calcium into cardiac ganglionic plexi suppresses autonomic nerve activity and postoperative atrial fibrillation. Heart Rhythm. 2019;16:597-605.
67. Ouyang F, Tilz R, Chun J, et al. Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010;122:2368-77.
68. Weerasooriya R, Khairy P, Litalien J, et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. J Am Coll Cardiol. 2011;57:160-6.
69. Driessen AHG, Berger WR, Krul SPJ, et al. Ganglion plexus ablation in advanced atrial fibrillation: the AFACT study. J Am Coll Cardiol. 2016;68:1155-65.
70. Katritsis DG, Pokushalov E, Romanov A, et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013;62:2318-25.
71. Srivastava P, Sharma PK, Muheem A, Warsi MH. Magnetic Nanoparticles: A Review on Stratagems of Fabrication an d its Biomedical Applications. Recent Pat Drug Deliv Formul. 2017;11:101-13.
72. Rahman MM, Islam MR, Akash S, et al. Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance. Biomed Pharmacother. 2022;153:113305.
73. Farzin A, Etesami SA, Quint J, Memic A, Tamayol A. Magnetic Nanoparticles in Cancer Therapy and Diagnosis. Adv Healthc Mater. 2020;9:e1901058.
74. Yu L, Scherlag BJ, Dormer K, et al. Autonomic denervation with magnetic nanoparticles. Circulation. 2010;122:2653-9.
75. Jiang W, Xu M, Qin M, et al. Role and mechanism of lncRNA under magnetic nanoparticles in atrial autonomic nerve remodeling during radiofrequency ablation of recurrent atrial fibrillation. Bioengineered. 2022;13:4173-84.
76. Yu L, Scherlag BS, Dormer K, et al. Targeted Ganglionated Plexi Denervation Using Magnetic Nanoparticles Carrying Calcium Chloride Payload. JACC Clin Electrophysiol. 2018;4:1347-58.
77. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552-65.
78. Lo LW, Chang HY, Scherlag BJ, et al. Temporary suppression of cardiac ganglionated plexi leads to long-term suppression of atrial fibrillation: evidence of early autonomic intervention to break the vicious cycle of “AF Begets AF”. J Am Heart Assoc. 2016:5.
79. Oh S, Choi EK, Zhang Y, Mazgalev TN. Botulinum toxin injection in epicardial autonomic ganglia temporarily suppresses vagally mediated atrial fibrillation. Circ Arrhythm Electrophysiol. 2011;4:560-5.
80. Sergeevichev D, Fomenko V, Strelnikov A, et al. Botulinum toxin-chitosan nanoparticles prevent arrhythmia in experimental rat models. Mar Drugs. 2020;18:410.
81. Lilei Y, Huang B, Jiang H. GW27-e1123 Left cardiac sympathetic denervation with neuron targeted nanoparticles improves cardiac function and reduces ventricular arrhythmia inducibility in a canine post-infarction heart failure model. J Am Coll Cardiol. 2016;68:C66-7.
82. Yu L, Lai Y, Jiang H. Photothermal inhibition of left stellate ganglion neural activity with gold nanorods to prevent ventricular arrhythmia. J Am Coll Cardiol. 2018;71:A285.
83. Schiffer M, Carls E, Wagner K, Engelbrecht B, Duerr D, Welz A, de la JM, Pfeifer A, Fleischmann K, Roell W. Transplantation of Cx43 expressing fibroblasts: an option for postinfarct arrhythmia prevention?. Thorac Cardiovasc Surg. 2019; 67(S 01):S1-S100.
84. Altshuler PJ, Schiazza AR, Luo L, et al. Superoxide dismutase-loaded nanoparticles attenuate myocardial ischemia-reperfusion injury and protect against chronic adverse ventricular remodeling. Adv Ther (Weinh). 2021;4:2100036.
85. Wang Y, Su W, Li Q, et al. Preparation and evaluation of lidocaine hydrochloride-loaded TAT-conjugated polymeric liposomes for transdermal delivery. Int J Pharm. 2013;441:748-56.
86. Mukhopadhyay S, Chakraborty P, Yusuf J, Goyal A, Tyagi S. Phenytoin in treatment of amiodarone-induced Torsades de pointes. Indian J Pharmacol. 2012;44:264-5.
87. Wang LW, Subbiah RN, Kilborn MJ, Dunn RF. Phenytoin: an old but effective antiarrhythmic agent for the suppression of ventricular tachycardia. Med J Aust. 2013;199:209-11.
88. Zhou X, Luo YC, Ji WJ, et al. Modulation of mononuclear phagocyte inflammatory response by liposome-encapsulated voltage gated sodium channel inhibitor ameliorates myocardial ischemia/reperfusion injury in rats. PLoS One. 2013;8:e74390.
89. Mathuria N, Royal ALR, Enterría-Rosales J, et al. Near-infrared sensitive nanoparticle-mediated photothermal ablation of ventricular myocardium. Heart Rhythm. 2022;19:1550-6.
90. Qi Y, Li J, Nie Q, et al. Polyphenol-assisted facile assembly of bioactive nanoparticles for targeted therapy of heart diseases. Biomaterials. 2021;275:120952.
91. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491-9.
92. Üstündağ-Okur N, Yurdasiper A, Gündoğdu E, Gökçe EH. Modification of solid lipid nanoparticles loaded with nebivolol hydrochloride for improvement of oral bioavailability in treatment of hypertension: polyethylene glycol versus chitosan oligosaccharide lactate. J Microencapsul. 2016;33:30-42.
93. Arshad I, Kanwal A, Zafar I, et al. Multifunctional role of nanoparticles for the diagnosis and therapeutics of cardiovascular diseases. Environ Res. 2024;242:117795.
94. Chen M, von Mikecz A. Formation of nucleoplasmic protein aggregates impairs nuclear function in response to SiO2 nanoparticles. Exp Cell Res. 2005;305:51-62.
95. Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol. 2002;39:935-42.
96. Hunt NJ, Mccourt PAG, Kuncic Z, Le Couteur DG, Cogger VC. Opportunities and Challenges for Nanotherapeutics for the Aging Population. Front Nanotechnol. 2022;4:832524.
97. Vinarov Z, Abrahamsson B, Artursson P, et al. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv Drug Deliv Rev. 2021;171:289-331.
